CEO, whats your excuse now mate ?

RESPIRI announces the details of their RPM reimbursement, how much they get paid per device and their monthly recurring revenue per month. What's your excuse now mate ?

Respiri earns US$50-60 for each device sale to RPM partner organisations and generates recurring revenues of US$10-20 per month from the ongoing RPM use of the device with revenue dependent upon the scope of futureservices outsourced to RPM partners.

Full Text of announcement
wheezo® REMOTE PATIENT MONITORING (RPM) SUCCESSFULLY REIMBURSED AND CLAIMED
BY PHYSICIANS.

Highlights:
• Respiri becomes the first Australian eHealth SaaS Company whose wheezo® medical device used for
Remote Patient Monitoring by physicians in USA is now reimbursed by Centers of Medicare and Medicaid
(CMS) in the USA.
• Respiri receiving recurring revenues per patient per month funded from these reimbursement claims and
from wheezo® device sales.
Respiri Limited (ASX:RSH; OTCQB:RSHUF)(“Respiri” or the “Company”), an eHealth SaaS Company supporting
respiratory health management is pleased to announce a key milestone in the execution of the Company USA
business strategy.
Respiri has become the first Australian medical device manufacturer to have its patented wheezo® device, used for
Remote Patient Monitoring (RPM) programs prescribed by physicians, to be successfully processed and receiving
reimbursement from Centers of Medicare and Medicaid Services (CMS) in the USA. The RPM program, delivered
by partner Access Telehealth, includes patient engagement and remote monitoring using the Access cloud-based
platform, Remotli. Although not financially material, this event marks a key milestone in the execution of the
Company’s USA business strategy.
CMS (and private insurers) provides RPM reimbursement to physicians based upon the eligibility of insured patients
across all 50 US states. RPM Current Procedural Terminology (CPT) reimbursement codes covered the RPM
solutions delivered through the Access Telehealth full-service premium model that includes patient engagement
using their cloud-based platform, Remotli, including RPM CPT codes 99453, 99454 and 99457, totaling
approximately USD124 per patient, per month to the claiming physicians.
Respiri generates monthly recurring revenues per patient when the wheezo® RPM program is successfully delivered
and reimbursed by CMS, in addition to device sales. The wheezo® medical device is currently being used by 20
patients across a number of medical institutions/healthcare organisations who have engaged with Respiri’s partner,
Access Telehealth, to use the wheezo® RPM program for patients who suffer from Respiratory Disorders, including
asthma and Chronic Obstructive Pulmonary Disease (COPD). These numbers are expected to continue to grow as
the wheezo® RPM program gains traction in the USA with a further 500 patients identified for onboarding in the short
term. Respiri earns US$50-60 for each device sale to RPM partner organisations and generates recurring revenues
of US$10-20 per month from the ongoing RPM use of the device with revenue dependent upon the scope of future
services outsourced to RPM partners.
CMS provides universal reimbursement coverage for eligible patients across all 50 US states. Medicare provides
insurance coverage for older Americans who are considered targets for RPM services. Most US private health
insurers also reimburse RPM services. RPM is also mandated in 28 of the 50 US states making RPM reimbursement
mandatory in those states.